Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion

Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete in...

Descripción completa

Detalles Bibliográficos
Autor principal: Pitoia, Fabián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077291/
https://www.ncbi.nlm.nih.gov/pubmed/33936613
http://dx.doi.org/10.1002/ccr3.3900
_version_ 1783684852881555456
author Pitoia, Fabián
author_facet Pitoia, Fabián
author_sort Pitoia, Fabián
collection PubMed
description Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with RAI‐R‐differentiated thyroid cancer who might otherwise have few treatment options.
format Online
Article
Text
id pubmed-8077291
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80772912021-04-29 Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion Pitoia, Fabián Clin Case Rep Case Reports Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with RAI‐R‐differentiated thyroid cancer who might otherwise have few treatment options. John Wiley and Sons Inc. 2021-02-20 /pmc/articles/PMC8077291/ /pubmed/33936613 http://dx.doi.org/10.1002/ccr3.3900 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Pitoia, Fabián
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
title Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
title_full Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
title_fullStr Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
title_full_unstemmed Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
title_short Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
title_sort complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an etv6‐ntrk3 gene fusion
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077291/
https://www.ncbi.nlm.nih.gov/pubmed/33936613
http://dx.doi.org/10.1002/ccr3.3900
work_keys_str_mv AT pitoiafabian completeresponsetolarotrectinibtreatmentinapatientwithpapillarythyroidcancerharboringanetv6ntrk3genefusion

Ejemplares similares